Pipeline Analysis of Salivary Gland Cancer report covers emerging therapies for the cancer in active clinical development stages including early and late stage clinical trials. Medical centers throughout the world are researching the causes and treatment of salivary gland cancer. This is a challenging disease to study as it is not common. So, knowledge about treating these cancers with chemotherapy is still evolving. Chemo drugs such as gemcitabine, capecitabine and oxaliplatin are now being tested for clinical trials and may provide more options for people with advanced salivary gland cancer. Other treatments are- Surgery and Radiation therapy. For more information visit the below URL http://www.marketresearchhub.com/report/salivary-gland-cancer-pipeline-review-h2-2016-report.html
Cancer Genetics, Inc. (CGI) is the leader in the field of personalized medicine. It offers cancer diagnostics and treatments tailoring the specific genetic profile of the individual. The diagnostic assays and products offered by the company are designed to increase treatment efficacy and reduce healthcare costs of the hematological, urogenital and HPV-associated cancers
Bharat Book Bureau provides the report, on “Market Outlook on Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline Insights, 2015”. The Report also provides Transitional Cell Cancer (Urothelial Cell Cancer) related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. [ https://www.bharatbook.com/healthcare-market-research-reports-511574/transitional-cell-cancer-urothelial-cell-cancer-pipeline-insights.html ]
Download Sample Brochure @ http://tinyurl.com/hwf2rlb ‘Nonmelanomatous Skin Cancer - Pipeline Review, H2 2015’, provides an overview of the Nonmelanomatous Skin Cancer’s therapeutic pipeline. Scope - The report provides a snapshot of the global therapeutic landscape of Nonmelanomatous Skin Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Nonmelanomatous Skin Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects -
RnRMarketResearch.com adds “Metastatic Pancreatic Cancer – Pipeline Review, H1 2015” to its store. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages.
RnRMarketResearch.com adds “Follicular Thyroid Cancer – Pipeline Review, H1 2015” to its store. This report provides comprehensive information on the therapeutic development for Follicular Thyroid Cancer, complete with comparative analysis at various stages.
Bharat Book Bureau provides the report, on “Market Forecast on Skin Cancer-Pipeline Insights [2015] ” The report provides the in-depth analysis of the pipeline assets across the Skin Cancer. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. https://www.bharatbook.com/healthcare-market-research-reports-511525/skin-cancer-pipeline-insights.html
Research Beam added a report on “Cancer Cachexia - Pipeline Review, H2 2015” Enquiry about report: http://www.researchbeam.com/cancer-cachexia-pipeline-review-h2-2015-market/enquire-about-report
Big Market Research has announced a new Report Package "Rectal Cancer Market- Size, Share, Trends, Forecast, Development, Situation, Future outlook, Potential 2019" Get Complete Report at: http://www.bigmarketresearch.com/rectal-cancer-pipeline-review-h2-2015-market This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Enquire about this report at: http://www.bigmarketresearch.com/report-enquiry/322342
Metabolomx develops and owns all worldwide rights to the breath test for cancer. It uses CSA technology which is a matrix of colored chemical indicators of diverse reactivities incorporated in a nanoporous sol-gel matrix.
The report analyzes innovation in prostate cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzed the deals landscape surrounding first-in-class products in prostate cancer, and pinpoints opportunities for in-licensing. For Further Details : http://www.bigmarketresearch.com/frontier-pharma-prostate-cancer-identifying-and-commercializing-first-in-class-innovation-market
LifeScienceIndustryResearch.com adds “Head and Neck Cancer – Pipeline Review, H1 2015” to its store. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages.
Global Markets Direct’s, ‘Fallopian Tube Cancer – Pipeline Review, H1 2015′, provides an overview of the Fallopian Tube Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages.
Ovarian Cancer Therapeutics in APAC Market covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC).
Colorectal Cancer Pipeline Review, 2015 provides an overview of Colorectal Cancer diagnostic tests currently in pipeline stage. Enquiry about report: http://www.researchbeam.com/colorectal-cancer-pipeline-review-2015-market/enquire-about-report
Prospective partners with the most attractive projects are expected to enhance and expand business potential and scope for uterine cancer therapy globally. Marketers are developing and designing in-licensing and out-licensing strategies based on the identification of emerging players with potentially strong product portfolio. They are also designing effective counter-strategies to gain competitive advantage. Visit : http://www.researchonglobalmarkets.com/uterine-cancer-pipeline-review-h2-2013.html
DelveInsights, Papillary Thyroid Cancer-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Papillary Thyroid Cancer.
Big Market Research present “PharmaPoint: Prostate Cancer - Global Drug Forecast and Market” Size, Share, Industry Trends, Demand, Analysis, Research, Report, Company Profiles, Forecast to 2023. Visit for more info @ http://www.bigmarketresearch.com/pharmapoint-prostate-cancer-global-drug-forecast-and-analysis-to-2023-market Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options.
This report provides comprehensive information on the therapeutic development for Metastatic Biliary Tract Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Browse full report @ http://bit.ly/1FfHsCY
Complete report is available @ http://goo.gl/1PClKP . This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects.
Oct 28, 2014, Mumbai, India: Bharatbook.com announces a report “Cancer Cachexia-Pipeline Insights, 2014”, provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Cancer Cachexia.
Large and Diverse Pipeline The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market. Get more about this report at: http://www.bigmarketresearch.com/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation-market
GBI Research, has released the pharma report -"Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies". The current Ovarian cancer therapeutics market is dominated by the use of generics - predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Detailed Report at: http://www.reportsandintelligence.com/ovarian-cancer-therapeutics-in-major-developed-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-surival-and-targeted-therapies-market
Complete Report is available @ http://goo.gl/zCSRFR . This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects.
"Head and neck cancer is a group of cancers that normally start in the squamous cells lining the mouth, voice box (larynx), throat (pharynx), salivary glands, nasal cavity, and paranasal sinuses. These cancers are grouped all together due to their location and because of head and neck surgeons – also known as otolaryngologists Phone : +91 989 023 3887 | +91 9049935685 Email : dr.jagdish3007@gmail.com Website: https://cancercarepune.com
Download Sample Brochure @ http://tinyurl.com/jhvh6av Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2016’, provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Download Sample Brochure@ http://tinyurl.com/h34axhg Marketintelreports ‘Pancreatic Cancer - Pipeline Review, H2 2015’, provides an overview of the Pancreatic Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects.
Big Market Research, Adrenocortical Carcinoma Adrenal Cortex Cancer Market, Size, Share, Global Industry, Growth, Trends, Forecast, Analysis, Pipeline Review 2014.Global Markets Direct’s, ‘Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2014’, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with comparative analysis.
Big Market Research has announced a new Report Package "Global Head and Neck Cancer Diagnostics Market - Size, Share, Trends, Forecast, Development, Situation, Future outlook, Potential 2019" Get Complete Report at: http://www.bigmarketresearch.com/global-head-and-neck-cancer-diagnostics-2015-2019-market Various types of malignant tumors grown in and around head and neck are collectively known as head and neck cancers. Most head and neck cancers usually begin in the squamous cells that line the moist mucosal surfaces inside the mouth, throat, and nose. This is often identified as squamous cell carcinoma. The cancers start in the oral cavity, nasal cavity, larynx, salivary glands, pharynx, and paranasal sinuses. Enquire about this report at: http://www.bigmarketresearch.com/report-enquiry/339904
GBI Research, the leading business intelligence provider, has released its latest research: Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics, which provides in-depth analysis of the Colorectal Cancer (CRC) therapeutics market in the eight major geographies of the US, Canada, the UK, France, Germany, Spain, Italy and Japan. The report provides an estimation of the market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth pipeline analysis, and deal analysis. Enquiry @ http://www.researchbeam.com/colorectal-cancer-therapeutics-in-major-developed-to-2020-increased-uptake-of-high-priced-drugs-to-offset-the-impact-of-generics-market/enquire-about-report
Big Market Research presents this report which provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC). Read The Complete Report On : http://www.bigmarketresearch.com/ovarian-cancer-therapeutics-in-asia-pacific-to-2020-off-patent-chemo-regimens-to-retain-dominance-despite-new-launches-market
Head and neck cancers (HNCs) are a heterogeneous group, consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth; the salivary glands; the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx; the nose, sinuses, and related structures; the larynx; and the thyroid. HNCs usually begin in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck — more than 80% of all HNCs are squamous cell carcinomas. HNCs are common in several regions across the globe and account for 600,000 new cases annually worldwide.
Metastatic Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Breast Cancer. Browse full report @ http://bit.ly/1wgFgSu
The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market. Enquiry @ http://www.researchbeam.com/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report
Metastatic Pancreatic Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Pancreatic Cancer. Browse full report @ http://bit.ly/1N6x2Gb
Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Ovarian Cancer. Browse full report @ http://bit.ly/1Ls5dLa
Dr PK Das is one of the best head and neck cancer doctors in India. He has the unique experience working in one of India’s premier medical institutes. He’s been treating cancer holistically for over two decades. Medical oncology and hematology are two of the doctor’s specializations. visit our website to book an appointment : https://doctorpkdas.com/
Metastatic Colorectal Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Colorectal Cancer. Browse full report @ http://bit.ly/1aJpHP4
Metastatic Nonseminomatous Testicular Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Nonseminomatous Testicular Cancer. Browse full report @ http://bit.ly/1Mx6RXf
Being an oracle in Head and Neck cancer management, he offers varied and technologically advanced treatment which brings back the hope of cancer sufferers..
Only one-third of patients present with localized H&N Cancer which is highly curable with surgery, ... Non-Small Cell Lung Cancer (NSCL): The Role of Radiation ...
Work-caused and work-related cancer is of minor significance in Scotland ... Where cancer problems exist, they reflect age, ... Bladder and Salivary cancer ...
Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck.To Know more about Head and Neck cancer see this link http://www.indiacarez.com/head_and_neck_cancer_treatment_in_india.html
Most head and neck cancers begin in the cells that line the mucosal surfaces in the head and neck area, e.g., mouth, nose, and throat. Mucosal surfaces are moist tissues lining hollow organs and cavities of the body open to the environment. Normal mucosal cells look like scales (squamous) under the microscope, so head and neck cancers are often referred to assquamous cell carcinomas. Some head and neck cancers begin in other types of cells. For example, cancers that begin in glandular cells are called adenocarcinomas.
Cancer Bronchique Non Petites Cellules Bilan fonctionnel et d op rabilit Docteurs J SEIGNEUR-D BRAUN Clinique Claude Bernard METZ INTRODUCTION Principes du bilan ...
Racial/Ethnic Disparities in Cancer Incidence, Survival and Treatment Linda C. Harlan, PhD, MPH National Cancer Institute Division of Cancer Control and Population ...
GBI Research, the leading business intelligence provider, has released its latest research, "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies", which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. Get more about this report at: http://www.bigmarketresearch.com/colorectal-cancer-therapeutics-in-asia-pacific-to-2020-improved-regional-healthcare-access-to-drive-uptake-of-high-cost-targeted-therapies-market
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications.
Big Market Research, Global PharmaPoint HER2-Positive Breast Cancer Drug Market Size, Share, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities, Segmentation, to 2023. HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic. This report forecasts that the two monoclonal antibodies that also target the HER2 receptor will ensure Roche still occupies over 95% of the market in 2023. The challenge for new entrants into the HER2-positive market is to find patient populations that are currently underserved, and can work cooperatively with Roche’s targeted therapies.
Big Market Research, Global Pharma Point Colorectal Cancer Drug Market Size, Share, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities, Segmentation to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. By 2023, the end of the forecast period, GlobalData projects CRC sales to rise to $8.11 billion in the 8MM, at a moderate Compound Annual Growth Rate (CAGR) of 4.9%. Major drivers of the growth of the CRC market over the forecast period include increasing CRC incident cases, the launch of premium-priced adjuvant and maintenance treatments for first-line metastatic disease, and the launch of pipeline agents for later-line CRC. Annualized Colorectal cancer therapeutics market revenue, annual cost of therapy, and treatment usage patterns in eight patient segments, forecast from 2013 to 2023.
This reports provides a deep insight on Bladder Cancer, includes Opportunity analysis and forecasts to 2017. This bladder cancer report published by Globaldata.
This report is an essential source of information and analysis on the global Vitiligo Therapeutics market. The report identifies the key trends shaping and driving the global Vitiligo Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. For more information : http://bit.ly/1uksROs
The report identifies the key trends shaping and driving the global Growth Hormone Deficiency (GHD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Growth Hormone Deficiency (GHD) Therapeutics sector. For more information : http://bit.ly/1HiKsNu
The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Unstable Angina Therapeutics sector. For more information : http://bit.ly/1y2gJRa